secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001178913-21-003507
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO
----------------------------------------------------------------------------

- Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.
- Net loss for Q3 2021 of $3.0M ($0.01/share) vs $1.2M loss in Q3 2020.
- R&D expenses $1.5M (up from $1.0M); G&A $1.4M (up from $0.2M) due to public company costs and share-based comp.
- Appointed Dale Pfost as CEO and Donald Marvin as CFO/COO; progressing three Phase 2 trials.
- Phase 2 data readouts expected: liver fibrosis H1 2022, PSC H2 2022; SSc trial starts early 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/0001178913-21-003507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer